Isotechnika keeps voclosporin focus on nephrology after failure in uveitis
This article was originally published in Scrip
Executive Summary
Lux Biosciences finally has ended its pursuit of US FDA approval for oral voclosporin in the treatment of non-infectious uveitis after the calcineurin inhibitor failed to meet its primary endpoint in a Phase III clinical trial, but the Canadian company that licensed the drug to US-based Lux - Isotechnika Pharma of Edmonton, Alberta - remains focused on nephrology indications for the immunosuppressant.